Publications by authors named "Chunchun Ao"
Article Synopsis
- Emerging research suggests that human umbilical cord mesenchymal stem cells (UC-MSCs) may help treat chemotherapy-induced premature ovarian failure (POF) by improving ovarian function and reducing cell death.
- The study evaluated the timing of UC-MSC treatment and its effects on ovarian health in a mouse model, finding that administering UC-MSCs on day 6 post-chemotherapy significantly enhanced ovarian function compared to later timing.
- UC-MSC-derived extracellular vesicles (EVs) demonstrated similar therapeutic effects, activating the PI3K/AKT signaling pathway to prevent apoptosis of ovarian cells, with clusterin (CLU) identified as a key protein in this protective mechanism.
Article Synopsis
- * Research indicates that mesenchymal stem cells, particularly those derived from human umbilical cord, can help reduce kidney damage and fibrosis in DN models.
- * The study found that these stem cells and their exosomes work by inhibiting the Hedgehog/SMO signaling pathway, which is linked to kidney fibrosis and epithelial-mesenchymal transition (EMT), providing a potential new therapeutic approach for DN.
Background: Owing to the characteristics of easier access in vitro, low immunogenicity, and high plasticity, human umbilical cord-derived mesenchymal stem cells (UC-MSCs) are considered as a promising cell-based drugs for clinical application. No internationally recognized technology exists to evaluate the pharmacokinetics and distribution of cell-based drugs in vivo.
Methods: We determined the human-specific gene sequence, Homo1, from differential fragments Homo sapiens mitochondrion and Rattus norvegicus mitochondrion.
Article Synopsis
- Diabetic nephropathy (DN) is a serious kidney condition related to diabetes, and current treatments are ineffective against its progression.
- Recent studies show that pyroptosis, a form of programmed cell death, in kidney cells significantly contributes to DN, and human umbilical cord mesenchymal stem cells (UC-MSCs) can help reduce kidney damage and inflammation in affected rats.
- Specifically, UC-MSCs increase levels of miR-342-3p, which helps prevent pyroptosis by targeting and inhibiting the Caspase1 pathway, suggesting a new potential approach for treating kidney diseases through miRNA-modified cell therapy.